Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Medtronic

Stryker

A number of MedTech companies are currently attempting to gain ground within the robotics-aided healthcare market.

The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks

There's a new surgical robot coming soon. Is the market big enough for da Vinci and a big competitor's rival system?

Is Medtronic About to Give Intuitive Surgical a Run for Its Money?

A. O. Smith

Verizon

Not every company deserves to be in your 50-year portfolio, but owning these three could pay off handsomely.

3 Stocks to Buy and Hold for the Next Fifty Years.

Intuitive Surgical reported a great Q2, with strong revenue growth in both systems and instruments/accessories.

Intuitive Surgical: Shares Still Attractive After Solid Q2

ISRG's earnings were impressive, but the stock saw little movement.

DCF Shows ISRG's Valuation Is Exactly Where It Needs To Be

Bristol-Myers

Myriad Genetics

Cancer is one of the toughest diseases to fight, and these companies are playing a great role in helping people combat it.

Three Cancer Treatment Stocks - to Buy Right Now

Guardant Health Inc

Illumina

My 3 Top Healthcare Stocks for Long-Term Investors

Amarin Corporation Plc

Teladoc

These three health care stocks deserve your undivided attention right now.

3 Top Healthcare Stocks; to Buy Right Now

AbbVie

Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.

5 Top Cancer-Fighting Stocks to Buy Now

Global Payments

NetEase

Block

Uber

Zoom Video

Former Tiger Cub’s top buys include ride-hailing IPO and remote conferencing IPO.

Philippe Laffont’s Top 6 Buys in the 2nd Quarter

Amazon

These fast-growing companies just keep getting better with each passing year.

3 High-Growth Stocks to Secure Your Financial Future

ABIOMED

Align Technology

DexCom

Shockwave Medical

These medical device stocks appear to have what it takes to be long-term winners.

5 Top Medical Device Stocks to Buy Now

Executive VP & CFO of Intuitive Surgical Inc (30-Year Financial, Insider Trades) Marshall Mohr (insider trades) sold 15,000 shares of ISRG on 07/29/2019 at an average price of $526.11 a share.

Intuitive Surgical Inc (ISRG) Executive VP & CFO Marshall Mohr Sold $7.9 million of Shares

Abbott Labs

Baxter

Becton, Dickinson and Co.

Boston Scientific

Edwards Lifesciences

Johnson & Johnson

Market caps for these medical device stocks are big. Most of them have been big winners, too.

10 Biggest Medical Device Stocks

Intuitive Surgical (ISRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Intuitive Surgical (ISRG) Gain on Rising Earnings Estimates?

Disney

Alphabet

Their competitive advantages and long-term growth prospects make these three stocks keepers.

3 Stocks I'm Never Selling: Disney, Alphabet & Intuitive Surgical

Intuitive Surgical (ISRG) reported its quarterly earnings results late today, amassing a profit that gained more than 18% year-over-year.
The post Intuitive Surgical Earnings: ISRG Stock Down Despite Q2 Profit Beat appeared first on InvestorPlace.

Intuitive Surgical Earnings: ISRG Stock Down Despite Q2 Profit Beat

Intuitive Surgical stock attempted a breakout Friday after the robotic surgery giant topped second-quarter earnings and sales estimates, though it saw a moderation in hernia procedures.
The post How One Key Metric Could Tug On Intuitive Surgical's Attempted Breakout appeared first on Investor's Business Daily.

How One Key Metric Could Tug On Intuitive Surgical's Attempted Breakout

More hospitals are using this new method to get systems in-house.

This Key Trend Continues at Intuitive Surgical

Robotic surgical system manufacturer Intuitive Surgical, Inc. (NASDAQ: ISRG) reported above-consensus second-quarter results Thursday.

Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts

Intuitive Surgical (ISRG) expects 2019 procedure growth within 16-17%.

Intuitive Surgical (ISRG) Q2 Earnings Beat, Guidance Narrowed

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q2 2019 Results - Earnings Call Transcript

Intuitive Surgical earnings of $3.25 per share beat estimates as $1.1 billion in sales also topped. But Intuitive Surgical stock slipped late Thursday.

Robotic Surgery Giant Crushes Earnings Forecasts, But Stock Dips

Penumbra

Neuronetics Inc

Along with issues around ongoing talcum and opioid exposure, some rivals may have been winning at the company’s expense.

5 Medtech Companies May Be Winning at Johnson & Johnson’s Expense

JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology.

News for Intuitive Surgical Stock (ISRG)